📰 Roche Susvimo News

Roche Susvimo News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Roche Susvimo. Real-time updates on events, politics, business and more.

BioBlast w/e 08 Dec 23

December 11, 2023

The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…

United States United Kingdom Bio Lyfgenia Astrazeneca Merck Lynparza Samsung Bioepi Byooviz Genentech Lucentis

Source: lexology.com

Outlook on the Age-related Macular Degeneration Global Market to 2030 - Players Include Bayer, Pfizer, Bausch Health and Amgen Among Others

December 14, 2022

/PRNewswire/ -- The "Age-related Macular Degeneration Market Size, Share & Trends Analysis Report by Product (Eylea, Lucentis, Beovu), by Disease Type (Wet...

United States Roche Susvimo Samsung Bioepis Laura Wood Lucentisf Hoffmann La Roche Ltd Key Company Market Share Analysis

Source: prnewswire.com

Global Age-related Macular Degeneration Market Report 2022

December 2, 2022

Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration Market Size, Share &amp; Trends Analysis Report by Product (Eylea,...

United States Roche Susvimo Lucentisf Hoffmann La Roche Ltd Roche Ltd National Eye Institute European Commission

Source: globenewswire.com

Roche's refillable eye implant becomes Eylea's latest threat

October 25, 2021

BioPharma

United States Roche Susvimo Novartis Beovu Samsung Bioepis Drug Administration On Brightfocus Foundation

Source: biopharmadive.com

Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or "wet" age-related macular degeneration (nAMD)

October 22, 2021

Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

Wills Eye Hospital United States Nathalie Meetz Levi Garraway Roche Susvimo Sileia Urech

Source: investegate.co.uk